A Study to Assess Effect of Glucocil® on Metabolic Health in Individuals With Prediabetes and Type 2 Diabetes Mellitus.

NCT ID: NCT06496893

Last Updated: 2024-07-11

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

NA

Total Enrollment

100 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-07-25

Study Completion Date

2024-12-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A randomized, double-blind, placebo-controlled study to assess the effect of Glucocil® on metabolic health in individuals with prediabetes and Type 2 Diabetes Mellitus.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

A randomized, double-blind, placebo-controlled study to assess the effect of Glucocil® on metabolic health in individuals with prediabetes and Type 2 Diabetes Mellitus

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pre Diabetes Type2 Diabetes Mellitus

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

A randomized, double-blind, placebo-controlled study
Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Active 1200 mg per soft gel capsule

Combination of Vitamin B1, B6, B12, D3, Chromium Picolinate, Proprietary Mulberry Leaf Extract, Cinnamon Bark Powder, Gymnema Sylvestre Extract, Insulina (Cissus Sicyoides) Leaf Extract, Alpha Lipoic Acid, Phellodendron Bark Extract (Berberine HCL), Cissus Quadrangularis Extract, Banaba Leaf Extract, \& Fish Oil.

Two soft gels to be taken with breakfast and two soft gels to be taken with dinner

Group Type ACTIVE_COMPARATOR

IP 1200 mg per soft gel capsule

Intervention Type DIETARY_SUPPLEMENT

Two soft gels to be taken with breakfast and two soft gels to be taken with dinner

Placebo (Soyabean oil) 1200 mg per soft gel capsule

Two soft gels to be taken with breakfast and two soft gels to be taken with dinner

Group Type PLACEBO_COMPARATOR

Placebo Comparator: Placebo 1200 mg per soft gel capsule

Intervention Type DIETARY_SUPPLEMENT

Two soft gels to be taken with breakfast and two soft gels to be taken with dinner

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

IP 1200 mg per soft gel capsule

Two soft gels to be taken with breakfast and two soft gels to be taken with dinner

Intervention Type DIETARY_SUPPLEMENT

Placebo Comparator: Placebo 1200 mg per soft gel capsule

Two soft gels to be taken with breakfast and two soft gels to be taken with dinner

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Males and females of age more than equal to 30 years and less than equal to 70 years.
2. Body mass index within 30 kg/m2 and 35 kg/m2 (both values included) with waist circumference above 40 inches (men) or 35 inches (women).
3. Cohort 1 (Only for prediabetes individuals)- Individuals diagnosed with prediabetes with OGTT (140 mg/dL to 199 mg/dL); HbA1c (5.7% to 6.9%) and fasting blood glucose level (between 100 mg/dL to 125 mg/dL).
4. Cohort 2 (T2DM)- Individuals newly diagnosed with Type 2 diabetes mellitus with HbA1c between 7% and 9% (both values included) and fasting blood glucose level in between 126 to 180 mg/dL.
5. Triglycerides between 150 mg/dL and 299 mg/dL (both values inclusive) and/or Low-Density Lipoprotein (LDL) in between 130 mg/dL and 189 mg/dL (both values inclusive).
6. Individuals having non-vegetarian diet for at least 2 days a week.
7. Non-smoker.
8. Individuals who are willing to not change their physical activity levels throughout the study period.
9. Individuals willing to complete all study-related questionnaires and to complete all clinical study visits.
10. Individuals ready to give voluntary, written informed consent to participate in the study.

Exclusion Criteria

1. Individuals who are exclusively vegetarians diet.
2. Individuals with Type 1 diabetes mellitus.
3. Individuals with Type 2 diabetes mellitus on medication.
4. Individuals with any other endocrine disorder.
5. Individuals who are currently on diuretics or thyroid supplements
6. Individuals on lipid-lowering therapies.
7. Individuals with uncontrolled hypertenstion as assessed by systolic over diastolic blood pressure (≥ 140/90 mmHg).
8. Individuals who are currently on antihypertensive medication.
9. Individuals with cardiac arrhythmia, impaired hepatic or renal function
10. Individuals having heart failure, coronary artery disease, hyperthyroidism, hypothyroidism, cancer or mental disease or any other serious disease requiring active treatment.
11. History of malignancy or stroke.
12. Chronic alcoholism: History and/or current cases of chronic alcohol consumption or heavy drinkers as defined by i.For men consuming more than 4 drinks on any day or more than 14 drinks/week ii. For women, consuming more than 3 drinks on any day or more than 7 drinks/week
13. Individuals taking concomitant medication known to alter blood sugar.
14. Individuals having treatment with herbal or any other supplements.
15. Any condition or abnormality that would compromise the safety of the individuals or the quality of the study data.
16. Use of another investigational product within 3 months of the screening visit.
17. Females who are lactating, pregnant or planning to be pregnant or taking any oral contraceptives
Minimum Eligible Age

30 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Vedic Lifesciences Pvt. Ltd.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Shourya clinic

Pune, Maharashta, India

Site Status

Shri balaji Multispeciality hospital,

Thāne, Maharashtra, India

Site Status

Dr.Govinds Clinic,

Jaipur, Rajashthan, India

Site Status

Upendra Medicare

Varanasi, Uttar Pradesh, India

Site Status

Arihant Hospital

Varanasi, Uttar Pradesh, India

Site Status

Countries

Review the countries where the study has at least one active or historical site.

India

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Dr. Shalini Srivastava,, MBBS, MD

Role: CONTACT

7738418890

Lalit Pawaskar, M.Pharm, PGDM

Role: CONTACT

7738418890

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Dr. Nikhil More, MBBS MD

Role: primary

8446512457

Dr. Hemant Ingole, MBBS, MD

Role: primary

8600848920

Dr Govid Rankawat, MBBS MD

Role: primary

7891368525

Dr. Gaurav Singh, MBBS MD

Role: primary

9555112643

Dr. Dilip Chaurasiya, MBBS,MD

Role: primary

7292022991

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

NH/231201/GC/DM

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Fiber Mix and Glycemic Response
NCT03334643 COMPLETED NA
Nutraceutical on Hyperglycemia
NCT04107922 COMPLETED PHASE3